From Pains To Gains, Human Genome Sciences Wades Through Tough Times – BIO India
This article was originally published in PharmAsia News
Executive Summary
From managing Wall Street expectations to working out smart trial designs, success at HGS is all about the processes, Thomas Watkins told BIO India attendees.
You may also be interested in...
Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?
With GlaxoSmithKline and Human Genome Sciences agreeing to a merger July 16, the key question for the multinational pharma becomes what it will do to strengthen sales for Benlysta, a lupus drug launched in 2011 that has fallen short of bullish commercial expectations.
Emerging Views On Emerging Markets: Goldman Sachs Global Healthcare Conference
In this periodic feature, PharmAsia News listens in at major industry events to hear what senior executives have to say about Asia and other emerging markets. In our last profile, we sat in on a recent Sanford Bernstein conference in New York ('Emerging Views On Emerging Markets: The Sanford Bernstein Strategic Decisions Conference,' June 7, 2011). For this profile, we zoom in on the 32nd annual Goldman Sachs Global Healthcare Conference, held June 7-9 in Rancho Palos Verdes, California.
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions
The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.